Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 99

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 99
---
 TAEUS technology for the foreseeable future. We anticipate that our expenses will increase substantially as we:

    ●
    advance the engineering design and development of our TAEUS technology;

    ●
    acquire parts and build finished goods inventory of the TAEUS FLIP system;

    ●
    complete regulatory filings required for marketing approval of our NAFLD TAEUS application in the United States, including clinical studies to advance our de novo application with the FDA;

    ●
    seek to hire a small internal marketing team to engage and support channel partners and clinical customers for our NAFLD TAEUS application;

    ●
    expand marketing of our NAFLD TAEUS application;

    ●
    advance development of our other TAEUS applications; and

    ●
    add operational, financial and management information systems and personnel, including personnel to support our product development, planned commercialization efforts and our operation as a public company.

It is possible that we will not achieve the progress
that we expect because the actual costs and timing of completing the development and regulatory approvals for a new medical device are
difficult to predict and are subject to substantial risks and delays. We have no committed external sources of funds except for our at-the-market
offering program with Lucid Capital Markets, LLC, the use of which may be limited due to registration statement rules relating to public
float. We do not expect that our existing cash will be sufficient for us to complete the commercialization of our NAFLD TAEUS application,
or to complete the development of any other TAEUS application and we will need to raise substantial additional capital for those purposes.
As a result, we will need to finance our future cash needs through public or private equity offerings, debt financings, corporate collaboration
and licensing arrangements or other financing alternatives. Our forecast of our financial resources is a forward-looking statement and
involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in
the Risk Factors section of this Annual Report on Form 10-K. We have based this estimate on assumptions that may prove to be wrong, and
we could utilize our available capital resources sooner than we currently expect.

Until we can generate a sufficient amount of revenue
from our TAEUS platform applications or through our DAT strategy, if ever, we expect to finance future cash needs through public or private
equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be